SEC Company Response from Huize Holding (HUIZ) — Nov 20, 2019
Huize Holding Ltd
Date: Nov. 20, 2019 · CIK: 0001778982 · Accession: 0001193125-19-296403
AI Filing Summary & Sentiment
File numbers found in text: 333-233614
Referenced dates: October 4, 2019
Letter
Division of Corporation Finance Office of Healthcare & Insurance Washington, D.C., 20549 Re: Huize Holding Ltd (CIK No. 0001778982) Amendment No. 1 to Registration Statement on Form F-1 (File No. 333-233614) Response to the Staff’s Comment Letter Dated October 4, 2019
Dear Mr. McCann, Ms. Westbrook, Mr. Vaughn and Mr. Wyman:
On behalf of our client, Huize Holding Ltd., a foreign private issuer organized under the laws of the Cayman Islands (the “Company”), we are filing herewith the Amendment No. 2 to the Company’s registration statement on Form F-1 (the “Registration Statement”) and certain exhibits via EDGAR with the Securities and Exchange Commission (the “Commission”).
Securities and Exchange Commission
November 20, 2019
Page
Concurrently with the filing of the Registration Statement, the Company is hereby in this letter setting forth the Company’s responses to the comments contained in the letter from the staff of the Commission (the “Staff”) dated October 4, 2019. The Staff’s comments are repeated below in bold and are followed by the Company’s responses. Capitalized terms used but not otherwise defined herein have the meanings set forth in the Registration Statement.
To facilitate the Staff’s review, we are separately delivering to you today five courtesy copies of the Registration Statement, marked to show changes to the registration statement filed with the Commission on September 25, 2019, as well as two copies of the filed exhibits.
The Company respectfully advises the Staff that it plans to file the preliminary prospectus with the price range for the proposed offering on or about November 29, 2019, and to commence the road show on or about December 2, 2019. In addition, the Company plans to request that the Staff declare the effectiveness of the Registration Statement on or about December 12, 2019, and will file joint acceleration requests in time before the requested effective time. The Company would appreciate the Staff’s timely assistance and support to the Company in meeting the proposed timetable for the offering.
Amendment No. 1 to Form F-1 filed on September 25, 2019
Management
Directors and Executive Officers, page 162
1. We note your disclosure that each of Messrs. Wei and Ge have agreed to serve as a director of the Company upon effectiveness of the registration statement. Please file the consent of these individuals as required by Securities Act Rule 436.
In response to the Staff’s comment, the Company has revised the disclosure on page II-5 and filed the consents of the independent director appointees as exhibits 23.4 and 23.5.
Description of Share Capital
Shareholders Agreement , page 184
2. With reference to Exhibit 4.5, please revise the disclosure on page 184 and elsewhere to clarify, if true, that SAIF IV Healthcare (BVI) Limited’s board representation rights do not terminate upon completion of the offering.
In response to the Staff’s comment, the Company has revised the disclosure on page 184 to clarify that SAIF IV Healthcare (BVI) Limited’s board representation rights do not terminate upon completion of the offering.
Exhibits
3. Please have counsel revise its Exhibit 5.1 opinion to remove the assumption in paragraph (d). Refer to Staff Legal Bulletin No. 19, Section II.B.3. Also, have counsel remove language in this opinion and in Exhibit 8.1 indicating that the opinion is in “Draft” form.
In response to the Staff’s comment, the Company has revised exhibits 5.1 and 8.1 accordingly and re-submitted the exhibits.
Securities and Exchange Commission
November 20, 2019
Page
General
4. We refer to prior comment 3 and reissue the last sentence of the comment. In this regard, the top three graphics give undue prominence to sales and revenues without regard to expenses and net income. With respect to the newly added “Adjusted Net Profit Margin” graphic, please revise your presentation of this non-GAAP financial measure to comply with Item 10(e) of Regulation S-K.
In response to the Staff’s comments regarding the prospectus artwork, the Company has revised the artwork accordingly.
* * *
Securities and Exchange Commission
November 20, 2019
Page
If you have any questions regarding the Draft Registration Statement, please contact the undersigned by phone at +86 21 6193 8210 or via e-mail at haiping.li@skadden.com. PricewaterhouseCoopers Zhong Tian LLP is the independent registered public accounting firm of the Company.
Very truly yours,
/s/ Haiping Li
Show Raw Text
CORRESP 1 filename1.htm CORRESP SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP A DELAWARE LIMITED LIABILITY PARTNERSHIP 世達國際律師事務所 JING AN KERRY CENTRE, TOWER II 46TH FLOOR 1539 NANJING WEST ROAD SHANGHAI 200040, CHINA TEL: (86-21) 6193-8200 FAX: (86-21) 6193-8299 www.skadden.com FIRM/AFFILIATE OFFICES BOSTON CHICAGO HOUSTON LOS ANGELES NEW YORK PALO ALTO WASHINGTON, D.C. WILMINGTON November 20, 2019 BEIJING BRUSSELS FRANKFURT HONG KONG LONDON MOSCOW MUNICH PARIS SÃO PAULO SEOUL SINGAPORE TOKYO TORONTO Confidential Mr. Joseph McCann Ms. Christine Westbrook Mr. Kevin Vaughn Mr. Franklin Wyman Division of Corporation Finance Office of Healthcare & Insurance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C., 20549 Re: Huize Holding Ltd (CIK No. 0001778982) Amendment No. 1 to Registration Statement on Form F-1 (File No. 333-233614) Response to the Staff’s Comment Letter Dated October 4, 2019 Dear Mr. McCann, Ms. Westbrook, Mr. Vaughn and Mr. Wyman: On behalf of our client, Huize Holding Ltd., a foreign private issuer organized under the laws of the Cayman Islands (the “Company”), we are filing herewith the Amendment No. 2 to the Company’s registration statement on Form F-1 (the “Registration Statement”) and certain exhibits via EDGAR with the Securities and Exchange Commission (the “Commission”). Securities and Exchange Commission November 20, 2019 Page 2 Concurrently with the filing of the Registration Statement, the Company is hereby in this letter setting forth the Company’s responses to the comments contained in the letter from the staff of the Commission (the “Staff”) dated October 4, 2019. The Staff’s comments are repeated below in bold and are followed by the Company’s responses. Capitalized terms used but not otherwise defined herein have the meanings set forth in the Registration Statement. To facilitate the Staff’s review, we are separately delivering to you today five courtesy copies of the Registration Statement, marked to show changes to the registration statement filed with the Commission on September 25, 2019, as well as two copies of the filed exhibits. The Company respectfully advises the Staff that it plans to file the preliminary prospectus with the price range for the proposed offering on or about November 29, 2019, and to commence the road show on or about December 2, 2019. In addition, the Company plans to request that the Staff declare the effectiveness of the Registration Statement on or about December 12, 2019, and will file joint acceleration requests in time before the requested effective time. The Company would appreciate the Staff’s timely assistance and support to the Company in meeting the proposed timetable for the offering. Amendment No. 1 to Form F-1 filed on September 25, 2019 Management Directors and Executive Officers, page 162 1. We note your disclosure that each of Messrs. Wei and Ge have agreed to serve as a director of the Company upon effectiveness of the registration statement. Please file the consent of these individuals as required by Securities Act Rule 436. In response to the Staff’s comment, the Company has revised the disclosure on page II-5 and filed the consents of the independent director appointees as exhibits 23.4 and 23.5. Description of Share Capital Shareholders Agreement , page 184 2. With reference to Exhibit 4.5, please revise the disclosure on page 184 and elsewhere to clarify, if true, that SAIF IV Healthcare (BVI) Limited’s board representation rights do not terminate upon completion of the offering. In response to the Staff’s comment, the Company has revised the disclosure on page 184 to clarify that SAIF IV Healthcare (BVI) Limited’s board representation rights do not terminate upon completion of the offering. Exhibits 3. Please have counsel revise its Exhibit 5.1 opinion to remove the assumption in paragraph (d). Refer to Staff Legal Bulletin No. 19, Section II.B.3. Also, have counsel remove language in this opinion and in Exhibit 8.1 indicating that the opinion is in “Draft” form. In response to the Staff’s comment, the Company has revised exhibits 5.1 and 8.1 accordingly and re-submitted the exhibits. Securities and Exchange Commission November 20, 2019 Page 3 General 4. We refer to prior comment 3 and reissue the last sentence of the comment. In this regard, the top three graphics give undue prominence to sales and revenues without regard to expenses and net income. With respect to the newly added “Adjusted Net Profit Margin” graphic, please revise your presentation of this non-GAAP financial measure to comply with Item 10(e) of Regulation S-K. In response to the Staff’s comments regarding the prospectus artwork, the Company has revised the artwork accordingly. * * * Securities and Exchange Commission November 20, 2019 Page 4 If you have any questions regarding the Draft Registration Statement, please contact the undersigned by phone at +86 21 6193 8210 or via e-mail at haiping.li@skadden.com. PricewaterhouseCoopers Zhong Tian LLP is the independent registered public accounting firm of the Company. Very truly yours, /s/ Haiping Li Haiping Li cc: Cunjun Ma, Chairman of the Board of Directors and Chief Executive Officer Tracey Chow, Director and Co-Chief Financial Officer, Huize Holding Limited Minghan Xiao, Co-Chief Financial Officer, Huize Holding Limited Vincent Yao, Partner, PricewaterhouseCoopers Zhong Tian LLP David T. Zhang, Esq., Partner, Kirkland & Ellis International LLP Steve Lin, Esq., Partner, Kirkland & Ellis International LLP Amanda Mi Tang, Esq., Partner, Kirkland & Ellis International LLP